Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the vaccine’s prospects and the broader implications. The analysts also discuss Roche/Genentech’s deal with Hanmi, which will add to the MNC’s obesity pipeline an asset that the pharma believes could be first in class, and the White House's pick of a Trump loyalist to lead FDA – a move that has revived questions of the agency's independence.View full story: https://www.biocentury.com/article/660596#CancerVaccines #Obesity #FDA #Oncology #DrugDevelopment00:00 - Introduction03:03 - Moderna11:12 - Genentech obesity deal15:08 - Trump's FDA pickTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text